Sebelius Kathleen 4
4 · Humacyte, Inc. · Filed Jun 17, 2024
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Sebelius Kathleen
Director
Transactions
- Exercise/Conversion
Stock Options (right to buy)
2024-06-14−39,389→ 0 totalExercise: $2.56From: 2018-09-01Exp: 2025-09-01→ Common Stock (39,389 underlying) - Award
Stock Options (right to buy)
2024-06-13+50,000→ 50,000 totalExercise: $7.20Exp: 2034-06-13→ Common Stock (50,000 underlying) - Exercise/Conversion
Common Stock
2024-06-14$2.56/sh+39,389$100,836→ 39,389 total
Footnotes (1)
- [F1]The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.